Abstract 1352P
Background
Advanced EGFR T790M-mutant non-small cell lung cancer (NSCLC) inevitably develops resistance to third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. Metabolic reprogramming supports EGFR-TKI resistance, while thorough metabolomics clinical studies are limited.
Methods
Here, we enrolled 202 NSCLC patients from phase I and IIa clinical studies and characterized responsive metabolic features of third-generation EGFR-TKI by metabolomics, genomics and proteomics.
Results
The most frequent concurrent driver gene mutations were TP53, RB1, and PIK3CA and non-driver gene PIK3CG. Shorter progression-free survival (PFS) was related to PIK3CG (HR=3.55, P=0.06) or RB1 (HR=2.56, P=0.05) mutations and RB1 mutation was also correlated with shorter overall survival (OS) (HR=3.08, P=0.012). Baseline plasma metabolites revealed responder (R) featured by elevated glycerophospholipid and non-responder (NR) characterized by increased unsaturated fatty acids. RB1 and PIK3CG mutations were positively correlated with unsaturated fatty acids and negatively associated with glycerophospholipids. Moreover, the circulating metabolic landscape implicated two distinct metabolic subtypes (C1 and C2), suggesting that subtype C2 with worse OS was characterized by PIK3CG mutation and higher unsaturated fatty acids. Proteomics revealed C1 harbored increased levels of biosynthesis of fatty acid, fatty acid degradation, and fatty acid metabolism pathways compared to the C1 subtype. In vitro experiments, Orlistat combined with BPI-7711 had reduced IC50 (508.08nM) in comparison with BPI-7711 alone (1328nM). Furthermore, we confirmed that exogenous fatty acids promoted cell viability upon BPI-7711 treatment (IC50=1704nM versus 1328nM) through decreasing EGFR expression. Meanwhile, fatty acids downregulated FASN and upregulated CPT1A expression, which may reduce the de nove synthesis of fatty acids and influence fatty acid oxidation.
Conclusions
This study revealed the metabolic landscape of advanced T790M-mutant NSCLC patients, providing the potential guide of personalized third-generation EGFR-TKI treatment and therapeutic target for overcoming resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1353P - Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Presenter: Jamie Feng
Session: Poster session 19
1354P - Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations
Presenter: Chien-Chung Lin
Session: Poster session 19
1355P - Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Presenter: Marta Brambilla
Session: Poster session 19
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
1358P - Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Presenter: Ernest Nadal
Session: Poster session 19
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Presenter: Marc Denis
Session: Poster session 19
1361P - Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Presenter: Shirish Gadgeel
Session: Poster session 19
1362P - Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Presenter: Charu Aggarwal
Session: Poster session 19